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Abstract
Aim: For EPs 7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic
effects in respiratory tract infections outside the strict indication for antibiotics have already been
demonstrated in adults. Now, a dose-ﬁnding study for EPs 7630 was performed in children and
adolescents.
Methods: A total of 400 patients (aged 6–18 years) were randomized to receive either 30 mg,
60 mg or 90 mg EPs 7630 or placebo daily. Primary outcome criterion was the change in the bronchi-
tis-speciﬁc symptoms (BSS) total score from day 0 to day 7.
Results: After 7 days of treatment, the change in the BSS total score was signiﬁcantly better in
the 60 mg and 90 mg groups compared with placebo without relevant differences between these two
dosages. Especially ‘coughing’, ‘sputum’ and ‘rales at auscultation’ improved under EPs 7630. Onset of
effect was faster, time of bed rest shorter and treatment outcome and satisfaction with treatment were
rated better. Tolerability was comparable with placebo in all treatment groups.
Conclusion: EPs 7630 is effective in acute bronchitis outside the strict indication for antibiotics in 6–18 years old
patients, with a dose of 60 mg or 90 mg daily offering the best beneﬁt⁄risk ratio. EPs 7630 signiﬁcantly reduces
the severity of symptoms, leads to a more favourable course of the disease and a faster recovery from acute
bronchitis compared with the placebo, and is well tolerated.
Re-use of this article is permitted in accordance with
the Creative Commons Deed, Attribution 2.5, which
does not permit commercial exploitation.
INTRODUCTION
Acute bronchitis is one of the most frequent health
complaints for which parents seek medical care for their
children. According to an extensive evaluation, non-inﬂu-
enza-related viral respiratory tract infections impose a
greater economic burden on the public health system than
many other clinical conditions (1,2). The common treat-
ment of acute bronchitis with antibiotics has been ques-
tioned because of concerns about the emergence of
antibiotic resistance and only scant evidence of beneﬁt (3–
5). According to expert opinions, antibiotic therapy is
mostly ineffective in acute bronchitis, unless the pathogen is
of bacterial origin and determined by an appropriate labora-
tory test (6,7). One therapeutic alternative in the ﬁrst-line
treatment of acute bronchitis outside the strict indication
for antibiotics, which has been approved for use in children
(‡1 year of age, Germany), is a herbal drug preparation from
the roots of Pelargonium sidoides, EPs 7630.
1 Pharmaco-
logical activities, including moderate direct antibacterial
and antiviral potencies and immunomodulatory capabili-
ties, have been demonstrated in vitro for EPs 7630 and its
isolated constituents. The immunomodulatory activities are
mediated mainly by the release of tumour necrosis factor
(TNF-a) and nitric oxides, the stimulation of interferon-b
and the increase in natural killer cell activity (8,9). Further
biological activities in vitro are enhanced phagocytosis, oxi-
dative burst and intracellular killing of human peripheral
blood phagocytes (10), improved ciliary beating (11) and
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AE, adverse event; ANCOVA, analysis of covariance; BSS, bron-
chitis-speciﬁc symptoms; EPs 7630, herbal preparation from the
roots of Pelargonium sidoides (1:8–10, extraction solvent: etha-
nol 11% (w⁄w): registered trademark in Germany); FGK, Frage-
bogen zum Gesundheitszustand fu ¨r Kinder (questionnaire for
health state of children); IMOS, integrative medicine outcomes
scale; IMPSS, integrative medicine patient satisfaction scale.
1EPs
  7630 is the active ingredient of the product Umckaloabo
  (ISO
Arzneimittel, Ettlingen, Germany).
Acta Pædiatrica ISSN 0803–5253
ª2010 The Author(s)/Journal Compilation ª2010 Foundation Acta Pædiatrica/Acta Pædiatrica 2010 99, pp. 537–543 537inhibition of the interaction between group A streptococci
and host epithelia (12). In animal studies, an improvement
of sickness behaviour in response to treatment with EPs
7630 has been observed (13). The clinical efﬁcacy and safety
of EPs 7630 as a liquid preparation have been demonstrated
in adult patients (14–19) as well as in children (19–21) suf-
fering from acute bronchitis or sinusitis. In two observa-
tional studies with children suffering from acute bronchitis
or severe exacerbation of chronic bronchitis (20,21), EPs
7630 was able to provide complete or partial remission of
symptoms in more than 80% of the children, and reduced
the severity of symptoms respectively. The tolerability was
very good with mild to moderate adverse events (AE) in
only 1.8% of patients (21). This study was performed to
identify the appropriate dose of EPs 7630 and to demon-
strate its efﬁcacy, safety and tolerability in the treatment of
patients aged 6–18 years suffering from acute bronchitis.
METHODS
Study design
The study was performed from February to May 2006 at 16
centres in Ukraine as a randomized, double-blind, placebo-
controlled clinical dose-ﬁnding study with 4 parallel treat-
ment groups. Individual duration of the study was 7 days.
During this time, 3 visits were scheduled (day 0; days 3–5;
day 7). The study was conducted according to Good Clini-
cal Practice, the declaration of Helsinki and legal regula-
tions. Approvals of the Ethics Committee and the
regulatory authorities were obtained prior to the start of
the clinical trial. To ensure the integrity and validity of the
study, an independent Case Assessment and Data Quality
Evaluation Committee (CADQEC) supervised the quality
of the data generated at the trial sites before and after
unblinding.
Patients
Male or female patients aged 6–18 years old suffering from
acute bronchitis with symptoms starting £48 h prior to
inclusion in the study and with a total score of bronchitis-
speciﬁc symptoms (BSS) ‡5 points at screening were
included in the study. Major exclusion criteria were: treat-
ment with antibiotics, bronchodilators or glucocorticoids
during the last 4 weeks, or with analgetics, secretolytics,
mycolytics or antitussiva during the last 7 days prior to
study inclusion; indication for treatment with antibiotics;
allergic asthma; tendency to bleed; severe heart, renal or
liver diseases and⁄or immunosuppression, known hyper-
sensitivity against P. sidoides; chronic obstructive pulmo-
nary disease and pregnancy. Patients and their legal
representatives respectively gave their written informed
consent in accordance with the legal requirements.
Study medication
After written informed consent, eligible patients were ran-
domly allocated to one of four treatment groups in a bal-
anced way (with a block size of four), according to a
computer-generated randomization list. This randomization
list was prepared by using the validated random number
generator R-Code. The length of the balanced blocks was
ﬁxed in a separate document that was withheld from the
study sites. The investigators received sealed emergency
envelopes for individual patients, all of which were returned
unopened after completion of the trial.
Patients were given EPs 7630, a herbal drug preparation
from the roots of P. sidoides (1:8–10), dried, extraction sol-
vent: ethanol 11% (w⁄w), as EPs 7630 ﬁlm-coated tablets
[3 · 10 mg (= 30 mg group), 3 · 20 mg (= 60 mg group) or
3 · 30 mg⁄day (= 90 mg group) EPs 7630] 30 min before
or after a meal for 7 consecutive days, or a matched placebo
for the same time period.
Measurements
The primary efﬁcacy variable was the change in the BSS
total score from day 0 to day 7 rated by the investigator.
The BSS total score consists of the ﬁve symptoms cough-
ing, sputum production, pulmonary rales at auscultation,
chest pain while coughing and dyspnoea, which are the
most important features associated with acute bronchitis
(22,23), rated on a scale from 0 (not present) to 4 (very
severe) and leading to a maximum total score of 20
points.
Secondary efﬁcacy variables were: treatment response
according to three criteria (BSS total score of <3 on day 7,
decrease in BSS total score of at least 7 points from day 0 to
day 7 and BSS total score <3 on day 7 combined with a
decrease in BSS total score of at least 7 points from day 0 to
day 7), onset of effect, change of individual symptoms of the
total score, change of general symptoms (e.g. ‘absence of
appetite’, ‘headache’ and ‘vomiting’) and health status of
patients using the questionnaires for health state of children
(FGK, Fragebogen zum Gesundheitszustand fu ¨r Kinder).
Additional parameters were bed rest duration and ability to
attend kindergarten, school or work. Treatment outcome
was assessed by both the investigator and the patient using
the Integrative Medicine Outcomes Scale (IMOS) consist-
ing of a 5-point rating scale (1 = ‘complete recovery’,
2 = ‘major improvement’, 3 = ‘slight to moderate improve-
ment’, 4 = ‘no change’ and 5 = ‘deterioration’). Satisfaction
with treatment was assessed using the Integrative Medicine
Patient Satisfaction Scale (IMPSS), a ﬁve-point scale com-
prising the ratings: 1 = ‘very satisﬁed’, 2 = ‘satisﬁed’,
3 = ‘undecided’, 4 = ‘dissatisﬁed’ and 5 = ‘very dissatisﬁed’.
Safety parameters were surveillance of AEs, laboratory
safety parameters and vital parameters. Prior to unblinding,
every AE was classiﬁed by the investigator in one of four
categories according to the data available with regard to the
possible causal relationship to the administration of
the study medication (probable – possible – unlikely – no
relationship).
Statistical methods
The primary objective of this study was to demonstrate the
efﬁcacy and to evaluate the safety and tolerability of three
doses of EPs 7630 in acute bronchitis. As a result of the
lack of empirical data, the form of the dose–response
EPs 7630 in children and adolescents with acute bronchitis Kamin et al.
538 ª2010 The Author(s)/Journal Compilation ª2010 Foundation Acta Pædiatrica/Acta Pædiatrica 2010 99, pp. 537–543relationship was unknown. As a consequence, there was
high uncertainty about the assumptions to be made for
sample size calculation and whether the desired power
would actually be achieved with a ﬁxed sample size design.
Thus, the study was planned and performed with an adap-
tive interim analysis (24). The primary outcome variable for
conﬁrmatory treatment group comparisons of efﬁcacy was
the intra-individual difference of the BSS total score
between day 0 and day 7. A closed testing procedure was
applied as follows (25). In the ﬁrst step, differences
between placebo and the three active dose levels were
investigated. If the corresponding null hypothesis (no dif-
ference between the active dose levels and placebo) could
be rejected, the null hypotheses stating no difference
between placebo and two active dose levels were tested for
all subsets of two active dose levels. For active dose levels
for which all related null hypotheses could be rejected, the
null hypotheses stating no difference between the active
dose level and placebo were tested. The global null hypoth-
eses (placebo vs. 30 mg vs. 60 mg vs. 90 mg and placebo vs.
30 mg vs. 60 mg; placebo vs. 30 mg vs. 90 mg; placebo vs.
60 mg vs. 90 mg) were tested using the Bartholomew test
for unknown but common variances (26). The three single
null hypotheses comparing each of the active dose levels
with placebo were tested with an analysis of covariance
(ANCOVA), with the factors ‘treatment group’ and ‘centre’
and the covariate ‘baseline value of the total score of BSS’.
The one-sided boundaries for early rejection or acceptance
of null hypotheses within the interim analysis were
a1 = 0.0152 and a0 = 0.20 respectively (overall one-sided
type I error rate a = 0.025) (24).
Regarding the secondary efﬁcacy variables, descriptive
statistical methods were used for the comparison of treat-
ment groups and accordingly, the resulting p-values have to
be interpreted in an exploratory manner. All statistics are
based on the full analysis set according to the intention-to-
treat principle using the last observation carried forward
method for missing values.
RESULTS
Disposition of patients and baseline characteristics
A total of 400 patients were included for screening and were
subsequently randomized to receive 30, 60 or 90 mg EPs
7630 or matching placebo daily. All patients were included
in the safety analysis. One patient in the 30 mg group could
not be analysed for efﬁcacy because of early dropout with-
out any post-baseline measurement (withdrawal of con-
sent). Thus, the full analysis set comprised 399 patients; 101
patients received placebo, 100 patients received 30 mg, 99
patients received 60 mg and 99 patients received 90 mg EPs
7630. The evaluation of baseline data (Table 1) revealed no
noticeable differences between the treatment groups at
baseline. Almost all patients took the medication exactly as
prescribed. The mean treatment duration was about 7 days
in all groups.
Primary outcome measure
The decrease in the BSS total score between day 0 and day 7
was more pronounced in the active treatment groups com-
pared with that in the placebo group [placebo: 3.3 ± 2.6,
EPs 7630 (30 mg): 3.6 ± 2.4, EPs 7630 (60 mg): 4.4 ± 2.4,
EPs 7630 (90 mg): 5.0 ± 1.9]. The conﬁrmatory aim of the
study was already reached at the interim analysis: All global
null hypotheses comparing placebo with all three or to com-
binations of two active dose levels could be rejected (each
p < 0.0001 except for the comparison placebo vs. 30 mg vs.
60 mg EPs 7630 with p = 0.0011, one-sided Bartholomew
tests). The subsequent pairwise comparisons of each active
treatment group with placebo using the ANCOVA model
revealed statistically signiﬁcant differences in the decrease
in the BSS total score for the EPs 7630 60 mg and 90 mg
groups (p = 0.0004 and p < 0.0001 respectively, two-sided
ANCOVA p-values).
A considerable difference in the BSS total score for the
EPs treatment groups was already observed on days 3–5
and increased – in a dose-dependent manner – further until
day 7, especially for the dosages of 60 mg and 90 mg. The
Table 1 Baseline data (mean ± SD or relative frequencies)
Placebo
n = 101
EPs 7630 (30 mg⁄day)
n=1 0 0
EPs 7630 (60 mg⁄day)
n=9 9
EPs 7630 (90 mg⁄day)
n=9 9
Gender
Male 50.5% 53.0% 51.5% 52.5%
Female 49.5% 47.0% 48.5% 47.5%
Age (years) 12.7 ± 3.7 12.5 ± 3.5 12.9 ± 3.7 12.6 ± 3.7
Weight (kg) 47.6 ± 15.1 46.4 ± 13.5 47.1 ± 13.7 47.0 ± 15.3
Height (cm) 155.6 ± 18.5 154.4 ± 17.4 155.7 ± 16.4 154.4 ± 17.3
BMI (kg⁄m
2) 19.0 ± 2.8 18.9 ± 2.4 19.9 ± 2.6 19.1 ± 3.5
BSS total score: individual symptoms
Coughing 2.5 ± 0.5 2.5 ± 0.6 2.4 ± 0.6 2.6 ± 0.6
Sputum production 0.8 ± 0.7 0.8 ± 0.7 0.8 ± 0.7 0.8 ± 0.8
Pulmonary rales at auscultation 2.0 ± 0.5 2.0 ± 0.6 1.9 ± 0.5 2.0 ± 0.6
Chest pain while coughing 1.4 ± 0.7 1.4 ± 0.7 1.3 ± 0.7 1.3 ± 0.7
Dyspnoea 0.2 ± 0.5 0.2 ± 0.5 0.3 ± 0.5 0.3 ± 0.5
BSS total score 6.8 ± 1.4 6.9 ± 1.6 6.8 ± 1.5 7.0 ± 1.5
Patients with BSS total score ‡7 53.5% 54.0% 55.6% 59.6%
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conﬁdence intervals are shown in Figure 1.
Secondary outcome measures
Treatment response calculated on the basis of the BSS total
scores was higher in the active treatment groups than in the
placebo group (Fig. 2). Statistically signiﬁcant differences
regarding criterion 1 were determined for the 60 mg and
90 mg EPs 7630 groups in comparison with placebo.
Regarding criteria 2 and 3, a signiﬁcant difference in the rate
of responders compared with placebo was observed for the
90 mg EPs 7630 group.
The mean decrease in the individual symptoms ‘cough-
ing’, ‘sputum’, ‘pulmonary rales at auscultation’, ‘chest pain
while coughing’ and ‘dyspnoea’ from day 0 to day 7 was
markedly more pronounced in the EPs 7630 (60 mg) and
EPs 7630 (90 mg) groups than in the placebo group. The
active treatment groups showed a signiﬁcant dose-depen-
dent advantage compared with placebo for the symptoms
‘coughing’ (p < 0.0001), ‘sputum’ (p = 0.0016) and ‘pulmo-
nary rales at auscultation’ (p < 0.0001) (Fig. 3). Pairwise
comparisons with placebo showed statistically signiﬁcant
advantages of EPs 7630 in the 60 mg and 90 mg group for
the symptoms ‘coughing’ (p = 0.0433 and p = 0.0002
respectively), ‘sputum’ (p = 0.0499 and p = 0.0048 respec-
tively) and ‘pulmonary rales at auscultation’ (p = 0.0014
and p < 0.0001 respectively, two-sided t-test, each).
A statistically signiﬁcant dose-dependent effect of EPs
7630 on the general symptoms ‘absence of appetite’
(p = 0.0234), ‘headache’ (p = 0.0112), ‘vomiting’
(p = 0.0142) from day 0 to day 7 could also be found (Bar-
tholomew test). This was conﬁrmed by pairwise compari-
sons with placebo, which revealed a signiﬁcant advantage
in the EPs 7630 (90 mg) group regarding the general symp-
toms ‘absence of appetite’ (p = 0.0128) and ‘headache’
(p = 0.0090).
The rate of patients in the EPs 7630 (60 mg) and EPs
7630 (90 mg) groups reporting the onset of effect before day
5 was higher than that in the placebo group. A statistically
signiﬁcant advantage regarding the onset of effect in the
EPs 7630 (60 mg) and EPs 7630 (90 mg) groups could be
demonstrated (p = 0.0060 and p < 0.0001 respectively, two-
sided Mantel–Haenszel v
2-test) (Fig. 4).
Treatment outcome as evaluated by the investigators and
patients by means of the IMOS showed a signiﬁcantly better
outcome compared with placebo (Fig. 5). The satisfaction
of patients according to the IMPSS was also better in the
EPs 7630 groups. Patients in the active treatment groups
(57.0% for EPs 7630 30 mg, 66.7% for EPs 7630 60 mg and
81.8% for EPs 7630 90 mg) were more often satisﬁed or
very satisﬁed than those in the placebo group (45.5%).
In all groups, an improvement in health status as assessed
using the FGK questionnaire was observed between day 0
and day 7. This improvement was more pronounced in the
EPs 7630 (60 mg) and EPs 7630 (90 mg) groups compared
with that in the placebo group. A pairwise comparison with
placebo (two-sided t-test) revealed a statistically signiﬁcant
advantage of the EPs 7630 (60 mg) and EPs 7630 (90 mg)
group over placebo for the FGK item ‘I am feeling ill’
(p = 0.0012 and p = 0.0001 respectively). In addition, the
EPs 7630 (90 mg) group showed a signiﬁcant improve-
ment over placebo for the items ‘I have trouble playing or
learning’ and ‘I sleep bad’ (p = 0.0063 and p = 0.0067
respectively).
Figure 1 Course of the total score of bronchitis-speciﬁc symptoms from day 0
to day 7.
Figure 2 Treatment response. Frequency of responders for 3 criteria: criterion
1: BSS total score <3 points at day 7 (*p = 0.0339 for 60 mg EPs 7630 and
p = 0.0001 for 90 mg EPs 7630 compared with placebo); criterion 2:
decrease in BSS total score of at least 7 points from day 0 to day 7
(*p = 0.0175 for 90 mg EPs 7630 compared with placebo); criterion 3: com-
bination of criteria 1 and 2 (*p = 0.0093 for 90 mg EPs 7630 as compared
with placebo) (two-sided v
2-test, each).
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attend kindergarten, school or work improved markedly in
all groups, especially in the EPs 7630 (60 mg) and EPs 7630
(90 mg) groups. At day 0, only 1 patient (1%) was able to
attend kindergarten, school or work in the placebo and
60 mg group respectively. At day 7, 33.7% (placebo), 35.0%
[EPs 7630 (30 mg)], 44.4% [EPs 7630 (60 mg)] and 53.5%
[EPs 7630 (90 mg)] of patients had regained this ability.
Safety analysis
A total of 80 AEs were observed in 77 of 400 patients
(19.3%). The most frequent AEs were gastrointestinal dis-
orders (11%). With 22.8% [23 AEs in 23 patients; EPs
7630 (30 mg) group], 17.2% [20 AEs in 17 patients; EPs




Figure 3 Courses of the bronchitis-speciﬁc symptoms ‘coughing’ (A), ‘sputum’
(B) and ‘pulmonary rales at auscultation’ (C) from day 0 to day 7.
Figure 4 Day of onset of treatment effect as reported by the patient.
Figure 5 Improvement of the treatment outcome. Percentage of patients
judged as completely recovered or showing major improvement by the investi-
gator (I) and patient (P).
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in the active treatment groups was similar to that in the
placebo group [17.8% (18 AEs in 18 patients)]. None of the
AEs was classiﬁed as serious. The frequency of patients with
suspected drug-related AEs was 5.9% [6 of 101 patients; EPs
7630 (30 mg) group], 5.1% [5 of 99 patients; EPs 7630
(60 mg) group], 5.1% [5 of 99 patients; EPs 7630 (90 mg)
group] and 4.8% (5 of 101 patients; placebo group). With
0.008, 0.008 and 0.007 events⁄days of exposure, the inci-
dence of AEs in the active treatment groups was in the range
of that of placebo (0.006 events⁄days of exposure), including
their putative causal relationship tothe study medication.
DISCUSSION
The results of this study demonstrate the efﬁcacy, tolerabil-
ity and safety of EPs 7630, a herbal drug preparation from
P. sidoides roots, administered as ﬁlm-coated tablets in 6–
18 years old patients. The primary outcome parameter, i.e.
improvement in the BSS total score from day 0 to day 7,
was superior in the EPs 7630 (60 mg) and the EPs 7630
(90 mg) groups compared with that in the placebo group.
As the deﬁnition of acute bronchitis is still under dis-
cussion and diagnosis is solely based on clinical ﬁndings,
without standardized diagnostic signs and sensitive or
speciﬁc conﬁrmatory laboratory tests (3,27), the develop-
ment of commonly accepted diagnostic criteria and vali-
dated scores is desirable. As a result of the current lack
of standardized criteria, all outcomes applied in this trial
are subjective. BSS total score, FGK, IMPSS and IMOS
used in this study are not validated but appear to be
associated with a clinical beneﬁt, as already shown in for-
mer trials (14,15).
The treatment groups were well balanced with respect to
baseline data. Family smoking was not documented in this
study, but patients with diseases known to be caused or
exacerbated by environmental tobacco smoke (e.g. allergic
asthma, chronic obstructive pulmonary disease) were
excluded from study participation.
The improvement in the individual symptoms as well as
other secondary outcome measures was clearly more pro-
nounced in the active treatment groups of 60 mg and 90 mg
EPs 7630 per day. Regarding the individual symptoms for
instance, the beneﬁt was most pronounced for the symp-
toms ‘coughing’ and ‘pulmonary rales at auscultation’,
which can be explained by an improvement in ciliary beat-
ing found in an in vitro study (11). This could be an impor-
tant mode of action independent of antibacterial activity,
because most episodes of acute bronchitis are of viral origin
(3,28). A beneﬁt in bacterial infections may be achieved by
the inhibitory effect of EPs 7630 on the interaction between
bacteria and epithelia (12,29). Therefore, EPs 7630 could be
considered as ﬁrst-line treatment for all types of bronchitis,
because even in diseases needing antimicrobial therapy, this
initial treatment can bridge the time between presentation
of the patient and the ﬁnal decision on an appropriate anti-
biosis, thus reducing the risk of uncritical antibiotic treat-
ment. Patients would beneﬁt from fast improvement of
symptoms irrespective of the actual cause of bronchitis, be it
of bacterial or viral origin.
The generally low incidence and severity of AEs in all
dose groups of EPs 7630 indicate a good tolerability and
safety also with higher concentrations of EPs 7630 in the
study population of this clinical trial.
This study conﬁrms former results on the efﬁcacy of EPs
7630 (14–21). In contrast to the previous studies performed
in children, which were conducted as open-label, post-
marketing surveillance studies (18–21), this randomized,
double-blind, placebo-controlled study describes the ﬁrst
clinical dose ﬁnding with EPs 7630 in schoolchildren and
adolescents with acute bronchitis. Based on the efﬁcacy and
safety results presented, a daily dose of 60 mg EPs 7630
could represent the optimal dose with respect to the bene-
ﬁt⁄risk ratio.
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